A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages 96-100

  Zolopa, Andrew ^a   Sax, Paul E ^b   Dejesus, Edwin ^c   Mills, Anthony ^d   Cohen, Calvin ^e   Wohl, David ^f   Gallant, Joel E ^g   Liu, Hui C ^h   Plummer, Andrew ^h   White, Kirsten L ^h   Cheng, Andrew K ^h   Rhee, Martin S ^h   Szwarcberg, Javier ^h  

^a STANFORD UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Anthony Mills MD Inc   (United States)

^e Boston Community Research Initiative of New England   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GILEAD SCIENCES   (United States)

Author keywords

cobicistat; efficacy; HIV; phase 3 randomized trial; safety; stribild

Indexed keywords

COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATININE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; VIRUS RNA;

ABNORMAL DREAMING; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

ADENINE; ADULT; ANTI-HIV AGENTS; CARBAMATES; CREATININE; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ORGANOPHOSPHONATES; OXAZINES; QUINOLONES; RNA, VIRAL; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876283495     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318289545c     Document Type: Article

References (20)

1. US Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents recommends a fixed-dose combination product of elvitegravir/cobicistat/tenofovir/emtricitabine as an alternative regimen in antiretroviral treatment-naive individuals with HIV-1 infection. Available at: http://www.aidsinfo.nih.gov/contentfiles/AdultARVStatementOnEVG- COBI-TDF-FTC.pdf. Accessed September 1, 2012.
2. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.
3. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricita-bine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439-2448.
4. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. October 2002. Available at: http://www.fda.gov/downloads/Drugs/Gui-danceComplianceRegulatoryInformation/ Guidances/ucm070968.pdf. Accessed April 1, 2012.
5. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39-48.
6. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
7. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efa-virenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-456.
8. Stellbrink H, Moyle G, Orkin C, et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-naïve HIV-1 infected subjects. ASSERT: 48-week result. Presented at: 12th European AIDS Conference; November 11-14, 2009; Cologne, Germany.
9. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse tran-scriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-237.
10. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/-ritonavir, each combined with tenofovir disoproxil fumarate/emtricita-bine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16:339-348.
11. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50:367-374.
12. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-1688.
13. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.
14. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricita-bine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23: 1547-1556.
15. Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9:213-224.
16. McGrath D, Zhu L, Thiry A, et al. Renal function in treatment-naïve subjects exposed to tenofovir/emtricitabine in combination with atazana-vir/ritonavir or lopinavir/ritonavir: 48-week results from the CASTLE study (BMS AI424138)[THPE0190]. Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
17. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritona-vir-boosted atazanavir plus co-formulated emtricitabine and tenofovir dis-oproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429-2438.
18. Rockstroh JK, DeJesus E, Henry K, et al. Elvitegravir/cobicistat/ emtricita-bine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1 infected patients. Presented at: 11th International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, United Kingdom.
19. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32-40.
20. Gilead Sciences. Stribild (elvitegravir, cobicistat, emtricitabine, teno-fovir disoproxil fumarate) US prescribing information. Available at: http://www.gilead.com/pdf/stribild-pi.pdf. Accessed October 15, 2012.